Rafferty Asset Management’s Cullinan Therapeutics CGEM Stock Holding History
Bought
Maintained
Sold
Other funds holding CGEM
LCM
KCM
SL
Rafferty Asset Management's CGEM Position: Q3 2026 in Review
Rafferty Asset Management reduced its Cullinan Therapeutics (CGEM) stake by 19% in Q3 2026, selling an estimated $246K and leaving 53,230 shares worth $817K. The position accounts for ﹤0.01% of the portfolio, ranked #809.
Rafferty Asset Management first reported a position in CGEM in Q4 2021 and has held it in 13 quarters since. The position peaked at $1.92M in Q3 2024. 182 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.
- Rafferty Asset Management held 53,230 shares of Cullinan Therapeutics worth $817K as of Q3 2026.
- Rafferty Asset Management sold 12,862 Cullinan Therapeutics shares in Q3 2026, an estimated $246K.
- Cullinan Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q3 2026, its #809 holding.
- Rafferty Asset Management first reported a position in Cullinan Therapeutics in Q4 2021 and has held it in 13 quarters since.
- Rafferty Asset Management's Cullinan Therapeutics position peaked at $1.92M in Q3 2024.
- 182 funds tracked by Wall St. Rank held Cullinan Therapeutics as of Q3 2026.
Based on Rafferty Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.